vTv Therapeutics (VTVT) News Today → This indicator is great for calling bottoms (From WealthPress) (Ad) Free VTVT Stock Alerts $23.38 -0.37 (-1.56%) (As of 09:30 AM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 8:00 AM | prnewswire.comCANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETINGMay 27 at 2:03 PM | finance.yahoo.comShareholders in vTv Therapeutics (NASDAQ:VTVT) are in the red if they invested three years agoMay 22, 2024 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Share Price Passes Above 50-Day Moving Average of $24.72May 22, 2024 | marketbeat.comvTv Therapeutics (NASDAQ:VTVT) Stock Passes Above 50-Day Moving Average of $24.72vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above 50 Day Moving Average of $24.72May 11, 2024 | finanznachrichten.devTv Therapeutics Inc.: vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate UpdateMay 10, 2024 | investorplace.comVTVT Stock Earnings: vTv Therapeutics Reported Results for Q1 2024May 9, 2024 | globenewswire.comvTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate UpdateMarch 19, 2024 | finance.yahoo.comCANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITMarch 13, 2024 | finanznachrichten.devTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateMarch 13, 2024 | globenewswire.comvTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateMarch 6, 2024 | investing.comvTv Therapeutics starts phase 3 trial for diabetes drugMarch 4, 2024 | investorplace.comThe Top 3 Healthcare Stocks to Buy on Weakness in 2024March 4, 2024 | globenewswire.comvTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 DiabetesMarch 1, 2024 | globenewswire.comvTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare ConferenceFebruary 29, 2024 | bizjournals.comvTv Therapeutics' stock doubles after raising $51 million from health care investors including JDRFFebruary 28, 2024 | msn.comWhy Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today?February 28, 2024 | finance.yahoo.comvTv Therapeutics Inc. (VTVT)February 28, 2024 | markets.businessinsider.comNasdaq Down 50 Points; US Crude Stocks Rise By 4.2M BarrelsFebruary 28, 2024 | marketwatch.comVTv Therapeutics Shares Surge on $51 Million Private PlacementFebruary 28, 2024 | marketbeat.comTrading was temporarily halted for "VTVT" at 11:02 AM with a stated reason of "LULD pause." Trading set to resume at 11:02 AM. February 28, 2024 | marketbeat.comTrading was temporarily halted for "VTVT" at 11:02 AM with a stated reason of "LULD pause."February 28, 2024 | marketbeat.comTrading was temporarily halted for "VTVT" at 11:02 AM with a stated reason of "LULD pause."February 28, 2024 | wsj.comvTv Therapeutics Inc. Cl AFebruary 28, 2024 | finance.yahoo.comvTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundFebruary 28, 2024 | globenewswire.comvTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundFebruary 22, 2024 | prnewswire.comCANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCEJanuary 31, 2024 | uk.investing.comvTv Therapeutics Inc (VTVT)November 27, 2023 | money.usnews.comvTv Therapeutics Inc - Ordinary Shares - Class ANovember 21, 2023 | bizjournals.comvTv Therapeutics regains compliance with Nasdaq after 1-for-40 reverse stock splitNovember 21, 2023 | marketbeat.comTrading was temporarily halted for "VTVT" at 07:11 PM with a stated reason of "News pending."November 15, 2023 | bizjournals.comvTv Therapeutics loses $6.7M in Q3, could lose spot on NASDAQ indexNovember 11, 2023 | benzinga.comvTv Therapeutics Stock (NASDAQ:VTVT) Earnings Dates and Earning CallsNovember 10, 2023 | finanznachrichten.devTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate UpdateNovember 9, 2023 | finance.yahoo.comvTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate UpdateNovember 8, 2023 | finance.yahoo.comvTv Therapeutics to Participate at the Stifel 2023 Healthcare ConferenceNovember 3, 2023 | bizjournals.comvTv Therapeutics appoints Dr. Thomas Strack as chief medical officerNovember 2, 2023 | finance.yahoo.comvTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical OfficerNovember 1, 2023 | finance.yahoo.comvTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 MillionOctober 19, 2023 | finance.yahoo.comOne vTv Therapeutics Insider Raised Their Stake In The Previous YearSeptember 27, 2023 | finance.yahoo.comCANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19September 26, 2023 | finance.yahoo.comCantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic CancerSeptember 18, 2023 | finance.yahoo.comCANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMAAugust 24, 2023 | finance.yahoo.comIs vTv Therapeutics Inc (VTVT) Modestly Undervalued?August 16, 2023 | finance.yahoo.comvTv Therapeutics reports $5.6 million net loss as prepares for reverse stock split to remain on NasdaqAugust 12, 2023 | finanznachrichten.devTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate UpdateAugust 11, 2023 | finance.yahoo.comvTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate UpdateAugust 10, 2023 | finance.yahoo.comCantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast CancerAugust 6, 2023 | msn.comNearly half of U.S. adults want weight-loss drugs – KFF pollJuly 12, 2023 | finance.yahoo.comVTVT - vTv Therapeutics Inc.July 6, 2023 | msn.comvTv Therapeutics Inc - (VTVT) Price Target Decreased by 33.33% to 2.04 Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Are You Positioned For The New Energy Goldrush? (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy. Click here to get all the information about it. VTVT Media Mentions By Week VTVT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTVT News Sentiment▼1.240.80▲Average Medical News Sentiment VTVT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTVT Articles This Week▼41▲VTVT Articles Average Week Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ACRS News LUMO News GALT News XOMA News ADCT News CRMD News MRSN News VNDA News NATR News XERS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTVT) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport Society[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe 7th Trillion Dollar Company?The Oxford ClubDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
